We believe that this attempt enables clinicians to choose appropriate treatment easier .
According to rapid development of chemotherapy in advanced non-small cell lung cancer ( NSCLC ) , the Japan Lung Cancer Society has been up date d its own guideline annually since 2010 .
Recently , we have had various types of chemotherapeutic drugs like kinase inhibitors or immune-checkpoint inhibitors .
Thus , the guideline proposes to categorize patients into three entities : ( 1 ) driver oncogene-positive , ( 2 ) PD-L1 ≥ 50 % , and ( 3 ) others .
Here , we report an English version of the Japan Lung Cancer Society Guidelines 2018 for NSCLC , stages IV
Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730).
PURPOSE We compared the efficacy of combination chemotherapy versus single-agent therapy in patients with advanced non-small-cell lung cancer . PATIENTS AND METHODS A total of 561 eligible patients were r and omly assigned to receive paclitaxel alone or in combination with carboplatin . RESULTS The response rate was 17 % in the paclitaxel arm and 30 % in the carboplatin-paclitaxel arm ( P < .0001 ) . Median failure-free survival was 2.5 months in the paclitaxel arm and 4.6 months in the carboplatin-paclitaxel arm ( P = .0002 ) . Median survival times were 6.7 months ( 95 % CI , 5.8 to 7.8 ) and 8.8 months ( 95 % CI , 8.0 to 9.9 ) , and 1-year survival rates were 32 % ( 95 % CI , 27 % to 38 % ) , and 37 % ( 95 % CI , 32 % to 43 % ) , respectively . The overall survival distributions were not statistically different : hazard ratio = 0.91 ( 95 % CI , 0.77 to 1.17 ; P = .25 ) . Hematological toxicity and nausea were more frequent in the combination arm , but febrile neutropenia and toxic deaths were equally low in both arms . There was no significant survival difference  in elderly patients . Performance status 2 patients treated with combination chemotherapy had a better survival rate than those treated with single-agent therapy ( P = .019 ) . CONCLUSION Combination chemotherapy improves response rate and failure-free survival compared with single-agent therapy , but there was no statistically significant difference in the primary end point of overall survival . The results in elderly patients were similar to younger patients . Performance status 2 patients had a superior outcome when treated with combination chemotherapy
We believe that this attempt enables clinicians to choose appropriate treatment easier .
According to rapid development of chemotherapy in advanced non-small cell lung cancer ( NSCLC ) , the Japan Lung Cancer Society has been up date d its own guideline annually since 2010 .
Recently , we have had various types of chemotherapeutic drugs like kinase inhibitors or immune-checkpoint inhibitors .
Thus , the guideline proposes to categorize patients into three entities : ( 1 ) driver oncogene-positive , ( 2 ) PD-L1 ≥ 50 % , and ( 3 ) others .
Here , we report an English version of the Japan Lung Cancer Society Guidelines 2018 for NSCLC , stages IV